Rafael Holdings, Inc. (RFL)
RFLNYSEBiotechnology: Pharmaceutical Preparations
$1.10
+0.0300 (+2.80%) today
Regular session, Nov 11, 1:48 PM ET
- Market cap
- $57.40m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.10 to $1.13
- 52-week range
- $0.9901 to $3.96
- Average volume
- 24.8k
- Previous close
- $1.07
Financials
| Quarter | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
| Revenue | $240.0k | $211.0k | $179.0k | $244.0k |
| Gross profit | $231.0k | $199.0k | $171.0k | $231.0k |
| Operating income | -$10.14m | -$6.66m | -$6.88m | -$9.73m |
| Net income | -$9.82m | -$6.42m | -$4.23m | -$9.18m |
Last four quarters: revenue $874.0k, margin -3390.7%, free cash flow –
News
8 latest- Rafael Holdings, Inc. Submits NDA for Remibetadex Following Phase 3 TransportNPC StudyFintel · 1 day ago
- Rafael Holdings Announces NDA Submission for Remibetadex and Reports Fiscal Year 2026 Financial ResultsFintel · Oct 29, 2026
- Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA FilingMarketBeat · Oct 4, 2026
- Wednesday Sector Laggards: Real Estate, Agriculture & Farm Products BNK Invest · Sep 30, 2026
- Rafael's Trappsol Cyclo Shows Significant Benefit In NPC Prespecified Analysis RTTNews · Sep 30, 2026
- Rafael Reports Phase 3 Trappsol Cyclo Data In NPC RTTNews · Sep 30, 2026
- Rafael Holdings Posts Q3 Net Loss Narrows; Stock Up RTTNews · Jun 12, 2026
- Rafael's TransportNPC Trial Complete Final Patient Visit Of Trappsol Cyclo For Niemann-Pick Disease RTTNews · Jun 10, 2026
The company
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol Cyclo), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C ('NPC') and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- rafaelholdings.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.